Loss of blood group antigen a in non-small cell lung cancer

John L. Gwin, Andres J P Klein-Szanto, Shi Yu Zhang, Pasha Agarwal, Andre Rogatko, Steven M. Keller

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Many human tumor cells display alterations in blood group antigen expression, and the loss of antigen A expression by non-small cell lung cancer (NSCLC) in blood group A patients has recently been associated with decreased survival. Methods: To confirm this finding, we performed a retrospective study of 62 NSCLC patients undergoing potentially curative resection between August 1987 and December 1991 who were blood group A and had paraffin-embedded primary lung cancer tissue suitable for immunohistological analysis of antigen A expression. Twenty-seven patients expressed antigen A in their tumors, whereas 35 had loss of antigen expression. Disease-free survival (DFS) curves were calculated for stage I (n=26) and IIIA (n=25) patients. Results: The two groups of patients with or without antigen A expression did not have significantly different DFS. A proportional hazards regression analysis identified no significant difference in the DFS of stage I patients with or without antigen A, but stage IIIA patients who had preservation of antigen A had significantly shorter DFS than did those who lost antigen A (p=0.0002). Conclusions: The loss of expression of antigen A by primary tumor cells was not a significant adverse prognostic factor in DFS in our series, and we would recommend further studies to define clearly the clinical importance of antigen A expression in pulmonary carcinoma.

Original languageEnglish (US)
Pages (from-to)423-427
Number of pages5
JournalAnnals of Surgical Oncology
Volume1
Issue number5
DOIs
StatePublished - Sep 1994
Externally publishedYes

Fingerprint

Blood Group Antigens
Non-Small Cell Lung Carcinoma
Antigens
Disease-Free Survival
Neoplasms
Paraffin
Lung Neoplasms
Retrospective Studies
Regression Analysis
Carcinoma
Lung
Survival

Keywords

  • Blood group A
  • Lung cancer
  • Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Gwin, J. L., Klein-Szanto, A. J. P., Zhang, S. Y., Agarwal, P., Rogatko, A., & Keller, S. M. (1994). Loss of blood group antigen a in non-small cell lung cancer. Annals of Surgical Oncology, 1(5), 423-427. https://doi.org/10.1007/BF02303816

Loss of blood group antigen a in non-small cell lung cancer. / Gwin, John L.; Klein-Szanto, Andres J P; Zhang, Shi Yu; Agarwal, Pasha; Rogatko, Andre; Keller, Steven M.

In: Annals of Surgical Oncology, Vol. 1, No. 5, 09.1994, p. 423-427.

Research output: Contribution to journalArticle

Gwin, JL, Klein-Szanto, AJP, Zhang, SY, Agarwal, P, Rogatko, A & Keller, SM 1994, 'Loss of blood group antigen a in non-small cell lung cancer', Annals of Surgical Oncology, vol. 1, no. 5, pp. 423-427. https://doi.org/10.1007/BF02303816
Gwin JL, Klein-Szanto AJP, Zhang SY, Agarwal P, Rogatko A, Keller SM. Loss of blood group antigen a in non-small cell lung cancer. Annals of Surgical Oncology. 1994 Sep;1(5):423-427. https://doi.org/10.1007/BF02303816
Gwin, John L. ; Klein-Szanto, Andres J P ; Zhang, Shi Yu ; Agarwal, Pasha ; Rogatko, Andre ; Keller, Steven M. / Loss of blood group antigen a in non-small cell lung cancer. In: Annals of Surgical Oncology. 1994 ; Vol. 1, No. 5. pp. 423-427.
@article{bc83c1962a944133b536c76be4177e79,
title = "Loss of blood group antigen a in non-small cell lung cancer",
abstract = "Background: Many human tumor cells display alterations in blood group antigen expression, and the loss of antigen A expression by non-small cell lung cancer (NSCLC) in blood group A patients has recently been associated with decreased survival. Methods: To confirm this finding, we performed a retrospective study of 62 NSCLC patients undergoing potentially curative resection between August 1987 and December 1991 who were blood group A and had paraffin-embedded primary lung cancer tissue suitable for immunohistological analysis of antigen A expression. Twenty-seven patients expressed antigen A in their tumors, whereas 35 had loss of antigen expression. Disease-free survival (DFS) curves were calculated for stage I (n=26) and IIIA (n=25) patients. Results: The two groups of patients with or without antigen A expression did not have significantly different DFS. A proportional hazards regression analysis identified no significant difference in the DFS of stage I patients with or without antigen A, but stage IIIA patients who had preservation of antigen A had significantly shorter DFS than did those who lost antigen A (p=0.0002). Conclusions: The loss of expression of antigen A by primary tumor cells was not a significant adverse prognostic factor in DFS in our series, and we would recommend further studies to define clearly the clinical importance of antigen A expression in pulmonary carcinoma.",
keywords = "Blood group A, Lung cancer, Survival",
author = "Gwin, {John L.} and Klein-Szanto, {Andres J P} and Zhang, {Shi Yu} and Pasha Agarwal and Andre Rogatko and Keller, {Steven M.}",
year = "1994",
month = "9",
doi = "10.1007/BF02303816",
language = "English (US)",
volume = "1",
pages = "423--427",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Loss of blood group antigen a in non-small cell lung cancer

AU - Gwin, John L.

AU - Klein-Szanto, Andres J P

AU - Zhang, Shi Yu

AU - Agarwal, Pasha

AU - Rogatko, Andre

AU - Keller, Steven M.

PY - 1994/9

Y1 - 1994/9

N2 - Background: Many human tumor cells display alterations in blood group antigen expression, and the loss of antigen A expression by non-small cell lung cancer (NSCLC) in blood group A patients has recently been associated with decreased survival. Methods: To confirm this finding, we performed a retrospective study of 62 NSCLC patients undergoing potentially curative resection between August 1987 and December 1991 who were blood group A and had paraffin-embedded primary lung cancer tissue suitable for immunohistological analysis of antigen A expression. Twenty-seven patients expressed antigen A in their tumors, whereas 35 had loss of antigen expression. Disease-free survival (DFS) curves were calculated for stage I (n=26) and IIIA (n=25) patients. Results: The two groups of patients with or without antigen A expression did not have significantly different DFS. A proportional hazards regression analysis identified no significant difference in the DFS of stage I patients with or without antigen A, but stage IIIA patients who had preservation of antigen A had significantly shorter DFS than did those who lost antigen A (p=0.0002). Conclusions: The loss of expression of antigen A by primary tumor cells was not a significant adverse prognostic factor in DFS in our series, and we would recommend further studies to define clearly the clinical importance of antigen A expression in pulmonary carcinoma.

AB - Background: Many human tumor cells display alterations in blood group antigen expression, and the loss of antigen A expression by non-small cell lung cancer (NSCLC) in blood group A patients has recently been associated with decreased survival. Methods: To confirm this finding, we performed a retrospective study of 62 NSCLC patients undergoing potentially curative resection between August 1987 and December 1991 who were blood group A and had paraffin-embedded primary lung cancer tissue suitable for immunohistological analysis of antigen A expression. Twenty-seven patients expressed antigen A in their tumors, whereas 35 had loss of antigen expression. Disease-free survival (DFS) curves were calculated for stage I (n=26) and IIIA (n=25) patients. Results: The two groups of patients with or without antigen A expression did not have significantly different DFS. A proportional hazards regression analysis identified no significant difference in the DFS of stage I patients with or without antigen A, but stage IIIA patients who had preservation of antigen A had significantly shorter DFS than did those who lost antigen A (p=0.0002). Conclusions: The loss of expression of antigen A by primary tumor cells was not a significant adverse prognostic factor in DFS in our series, and we would recommend further studies to define clearly the clinical importance of antigen A expression in pulmonary carcinoma.

KW - Blood group A

KW - Lung cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0028506596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028506596&partnerID=8YFLogxK

U2 - 10.1007/BF02303816

DO - 10.1007/BF02303816

M3 - Article

C2 - 7850544

AN - SCOPUS:0028506596

VL - 1

SP - 423

EP - 427

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 5

ER -